

DAFTAR PUSTAKA

American Cancer Society, 2011, *Breast Cancer Facts & Figures 2009-2010*,

American Cancer Society, inc., Atlanta.

American Cancer Society, 2015, *What are Hot Flushes and Sweating*,

<https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/hot-flashes-sweating/what-are-hot-flashes-and-sweating.html>

26 Mei 2020.

American Cancer Society, 2019a, *What is Breast Cancer?*,

<https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html> 26 Mei 2020.

American Cancer Society, 2019b, *Chemotherapy for Breast Cancer*,

<https://www.cancer.org/cancer/breast-cancer/treatment/chemotherapy-for-breast-cancer.html> 26 Mei 2020.

American Cancer Society, 2019c, *Radiation for Breast Cancer*,

<https://www.cancer.org/cancer/breast-cancer/treatment/radiation-for-breast-cancer.html> 26 Mei 2020.

American Cancer Society, 2019d, *Hormone Therapy for Breast Cancer*,

<https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html> 26 Mei 2020.

American Cancer Society, 2019e, *Breast Cancer Risk and Prevention*,

<https://www.cancer.org/cancer/breast-cancer/risk-and-prevention.html> 26 Mei 2020.

American Cancer Society, 2019f, *Breast Cancer Stages*,

<https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/stages-of-breast-cancer.html> 26 Mei 2020.

American Cancer Society, 2019g, *Breast-conserving Surgery*,

<https://www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-cancer/breast-conserving-surgery-lumpectomy.html> 26 Mei 2020.

American Cancer Society, 2019h, *How Radiation Therapy Is Used to Treat Cancer*,

<https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation>, diakses pada 07 Juli 2020.

Arumingsih, S.I, Choridah, L., Supriatna, Y., 2015, Perbandingan Kejadian *Fatty Liver* Pada Ultrasonografi Penderita Kanker Payudara dengan dan Tanpa Terapi Tamoxifen, *Jurnal Radiologi Indonesia*, Volume 1 Nomor 1, Mei 2015.

Assi, H.I., Kakati, R.T., Attieh, R.M., Khoury, J., Sukhon, F., Berro, J., Sbaity, E., Salem, Z., Tfaily, A., Alameh, A.I., Saghir, N.E., 2020, Fertility in Breast Cancer Survivors in the Middle East: A Retrospective Study, *The Breast*, 52 (2020) 58-63, <https://doi.org/10.1016/j.breast.2020.04.010>.

Azim, H.A., Shohdy, K.S., Kaldas, D.F., Kassem, L., Azim Jr, H.A., 2020, Adjuvant Ovarian Function Suppression And Tamoxifen In Premenopausal Breast Cancer Patients: A Meta-Analysis, *Current Problems In Cancer*, 11:57, <https://doi.org/10.1016/j.currproblcancer.2020.100592>.

Balkenhol, M.C.A., Vreuls, W., Wauters, C.A.P., Mol, S.J.J., Laak, J.A.W.M.,

Bult, P., 2020, Histological Subtypes in Triple Negative Breast Cancer

Are Associated With Specific information On Survival, *Annals of*

Diagnostic Pathology, 46 (2020) 151490,

<https://doi.org/10.1016/j.anndiagpath.2020.151490>.

Balkhi, B., Alqahtani, S., Altayyar, W., Ghawaa, Y., Alqahtani, Z., Alsaleh, K.,

Asiri, Y., 2020, Drug Utilization and Expenditure Of Anticancer Drugs

for Breast Cancer, *Saudi Pharmaceutical Journal*,

<https://doi.org/10.1016/j.jsps.2020.04.007>.

Breast Cancer Organization, 2014, *Tamoxifen's Benefit Long-Lasting for High*

Risk Women,

<https://www.breastcancer.org/research-news/tamoxifens-benefits-last-long-for-high-risk>

07 Juli 2020.

Breast Cancer Organization, 2019, *Radiation Therapy*,

<https://www.breastcancer.org/treatment/radiation> 26 Mei 2020.

Breast Cancer Organization, 2020, *Age*,

<https://www.breastcancer.org/risk/factors/age> 07 Juli 2020.

Breast Cancer Organization, 2020, *Hormonal Therapy*,

<https://www.breastcancer.org/treatment/hormonal> 07 Juli 2020.

Breast Cancer Organization, 2020, *Tamoxifen (Brand Names : Nolvadex,*

Soltamox),

<https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen> 07

Juli 2020.

Breast Cancer Organization, 2020, *Vaginal Dryness*,

https://www.breastcancer.org/treatment/side_effects/vaginal_dry 26 Mei
2020.

Budiman, A., Khambri, D., Bachtiar, H., 2013, Faktor yang Mempengaruhi
Kepatuhan Berobat Pasien yang Diterapi Dengan Tamoxifen Setelah
Operasi Kanker Payudara, *Jurnal Kesehatan Andalas*, 2013;2(1).

Chirgwin, J.H., Hurer, A.G., Coates, A.S., Price, K.N., Ejlertsen, B., Debled, M.,
Gelber, R.D., Golhirsch, A., Smith, I., Rabaglio, M., Forbes, J.F., Neven,
P., Lang, I., Colleoni, M., Thurlimann, B., 2016, Treatment Adherence
and Its Impact on Disease-Free Survival in the Breast international
Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence,
Journal of Clinical Oncology, 34(21):2452-2459. DOI:
10.1200/JCO.2015.63.8619

Cohen, I., 2011, *Ovarian Hiperstimulation Syndrome in Patient Treated with
Tamoxifen For Breast Cancer*, Published in Fertility and sterility:147.

Damajanti, Heny, 2014, *Perbedaan Kejadian Kista Ovarium pada Penggunaan
Tamoxifen Penderita Kanker Payudara dengan Pemeriksaan
Ultrasonografi*, Disertasi, Fakultas Kedokteran Universitas Gadjah Mada,
Yogyakarta.

Dipiro, J.T., Dipiro, C.V., Wells, B.G., Scwinghammer, T.L., 2008, *The Seventh
Edition of The Benchmark Evidence-Based Pharmacotherapy*,
McGraw-Hill Companies Inc., USA.

Faisel, Citra Tri Wahyumi, 2012, *Gambaran Efek Samping Kemoterapi Berbasis Antrasiklin pada Pasien Kanker Payudara di RSUD Dokter Soedarso Pontianak*, Fakultas Kedokteran Universitas Tanjungpura, Pontianak.

Firmansyah, Rully, Daan Khambri, Edison, Zelly Dia Rofinda, 2015, *Kejadian Demam Neutropenia pada Pasien Kanker Payudara yang Mendapat Kemoterapi*, Fakultas Kedokteran Universitas Andalas, Padang Vol. 38 No.1.

Forbes, J.F., Sestak, I., Howell, A., Boanni, B., Bundred, N., Levy, C., Minckwitz, G., Eiermann, W., Neven, P., Stierer, M., Holcombe, C., Coleman, R.E., Jones, L., Ellis, I., Cuzick, J., 2016, Anastrozole Versus Tamoxifen for the Prevention of Locoregional and Contralateral Breast Cancer in Postmenopausal Women with Locally Excised Ductal Carcinoma in Situ (Ibis-Ii Dcis): a Double-Blind, Randomised Controlled Trial, *Lancet*, 387: 866–73. [http://dx.doi.org/10.1016/S0140-6736\(15\)01129-0](http://dx.doi.org/10.1016/S0140-6736(15)01129-0).

Freedman, R.R., 2014, Menopausal Hot Flashes: Mechanisms, Endocrinology, Treatment, *Journal of Steroid Biochemistry and Molecular Biology*, 142 (2014) 115–120, <http://dx.doi.org/10.1016/j.jsbmb.2013.08.010>.

Gale, D. Charette, J., 2000, *Rencana Asuhan Keperawatan Onkologi*, Diterjemahkan I Made Kasiasa, EGC, Jakarta.

Garber, J.E., Halabi, S., Tolaney, S.M., Kaplan, E., Archer, L., Atkins, J.N., Edge, S., Shapiro, C.L., Dressler, L., Paskett, E.M., Kimmick, G., Orcutt, J., Scalzo, A., Winer, E., Levine, E., Shahab, N., Berliner, N., 2010, *Factor*

*V Leiden Mutation and Thromboembolism Risk in Women Receiving
Adjuvant Tamoxifen for Breast Cancer*, Oxford University Press, Vol.
102. DOI: 10.1093/jnci/djq211

Globocan, 2008, *Breast Cancer incidence and Mortality Worldwide in 2008*,
<http://globocan.iarc.fr/factsheets/cancer/breast.asp>.

Hackshaw, A., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R.,
dan Baum, M., 2011, Long-Term Benefits Of 5 Years Of Tamoxifen:
10-Year Follow-Up Of a Large Randomized Trial In Women At Least
50 Years Of Age With Early Breast Cancer, *Journal Of Clinical
Oncology*, Volume 29 Number 13.

Houts, A.C., Olufade, T., Shenolikar, R., Walker, M.S., Schwartzberg, L.S., 2019,
Treatment Patterns, Clinical Outcomes, Health Resource Utilization, and
Cost in Patients with Brca-Mutated Metastatic Breast Cancer Treated in
Community Oncology Settings, *Cancer Treatment and Research
Communication*, 19 (2019) 100121.
doi.org/10.1016/j.ctarc.2019.100121.

Inoue, H., Hirano, A., Ogura, K., Kamimura, M., Hattori, A., Yukawa, H.,
Sakaguchi, S., Tanaka, N., Matsuoka, A., Kodera, A., Shimizu, T., 2019,
Breast-Conserving Surgery Without Radiation in Elderly Women with
Early Breast Cancer, *Surgical Oncology*, 31:22-25,
<https://doi.org/10.1016/j.suronc.2019.08.008>.

Imamoglu G.I., Eren T., Arzu O., Yildirim, N., Karacin, C., Baylan, B., 2019, *Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?*, *Cureus*, 11(8): e5417. DOI 10.7759/cureus.5417

Kemenkes RI, 2018, *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara*, Kemenkes RI, Jakarta.

Kim, M.K., Shin, H.C., 2020, *Risk Factors for Tamoxifen-Induced Ovarian Hyperstimulation in Breast Cancer Patients*, Elsevier Inc., <https://doi.org/10.1016/j.clbc.2020.01.003>.

Kligman, L., & Younus, J., 2010, *Management of Hot Flashes in Women with Breast Cancer*, *Current Oncology*, Vol 17, No 1.

Kurniawan, Okky, 2014, *Gambaran Efek Samping Obat Kemoterapi pada Pasien Kanker Payudara RSUP Dr. Sardjito Yogyakarta Periode Tahun 2012*, Skripsi, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.

Kwon, E., Kim, M., Choi, E., Park, Y., Kim, C., 2019, *Tamoxifen-Induced Acute Eosinophilic Pneumonia in a Breast Cancer Patient*, *International Journal of Surgery Case Report*, 60 (2019) 186-190. <https://doi.org/10.1016/j.ijscr.2019.02.026>.

Lee, C.I., Fox, P., Blakrishnar, B., Balleine, R.L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H., Wilcken, N., 2019, *Tamoxifen-Induced Severe Hot Flashes and Endoxifen Levels: is Dose Reduction a Safe and Effective Strategy?*, *The Breast*, Vol 46:52-57.

Lee, S., Kim, Y.H, Kim, S.C., Joo, J.K., Seo, D.S., Kim,K.H., Lee, K.S., 2018,
*The Effect of Tamoxifen Therapy on The Endometrium and Ovarian Cyst
Formation in Patients with Breast Cancer*, Obstetrics and Gynecology
Science, Vol 61(5): 615-620. doi.org/10.5468/ogs.2018.61.5.615

Liana, L.K., & Lirauka, F., 2012, *Karakteristik Pasien Kanker Payudara dan
Penanganannya di RSUD Arifin Achmad Pekanbaru Periode Januari
2010-Desember 2012*, Universitas Kristen Maranatha, Bandung.

Lin, H.F., Liao, K.F., Chang, C.M., Lin, C.L., Lai, S.W., Hsu, C.Y., 2018,
*Correlation of The Tamoxifen Use with The increased Risk of Deep Vein
Thrombosis and Pulmonary Embolism in Elderly Women with Breast
Cancer*, Wolters Kluwer Health Inc. 97:51(e12842).
doi.org/10.1097/MD.00000000000012842.

Living Beyond Breast Cancer Organization, 2019, FAC : *Fluorouracil,
Adriamycin,
Cytoxan*,<https://www.lbbc.org/learn/treatments-and-research/chemotherapy/common-chemotherapy-regimens/fac-fluorouracil-adriamycin> 07 Juli
2020.

Lorizio, W., Wu, A.H.B., Rugo, H., Tchu, S., Kerlikowske, K., Ziv, E., 2012,
*Clinical and Biomarker Predictors of Side Effects from Tamoxifen,
Breast Cancer Rest Treatment*, 132(3):1107-1118.
doi:10.1007/s10549-011-1893-4

Marsanti, Febriana, C.A., Ibrahim, A., Rahmawati, D., 2016, *Karakteristik dan Pola Pengobatan Pasien Kanker Payudara di RSUD Abdul Wahab Sjahranie*, Fakultas Farmasi Universitas Mulawarman, Samarinda.

Martha, J.W., Soedarsono, D.A., Iqbal, M., Astuti, A., Martanto, E., Akbar, M.R., Sumantra, I.G., 2020, The Effect of Prophylactic Carvedilol on Subclinical Left Ventricular Dysfunction After 1 Cycle FAC Chemotherapy In Breast Cancer Patients, *IJC Heart & Vasculature*, 29 (2020) 100575, doi.org/10.1016/j.ijcha.2020.100575.

Megantari, Irene, 2007, *Evaluasi Pemilihan dan Penggunaan Antibiotik pada Pasien Kanker Payudara Pasca Kemoterapi di RSUP Dr. Sardjito Yogyakarta 2005*, Skripsi, Fakultas Farmasi Universitas Sanata Dharma, Yogyakarta.

Mulyasari, A.D., Bahar,H., Ismail, C.S., 2017, Analisis Faktor Risiko Kanker Payudara Pada RSUD. Bahteramas Kota Kendari Provinsi Sulawesi Tenggara Tahun 2017, *Jurnal Ilmiah Mahasiswa Kesehatan Masyarakat*, Vol. 2 No. 6 ISSN 250-731.

Nakamura, K., Okada, E., Ukawa, S., Hirata, M., Nagai, A., Yamagata, Z., Kiyohara, Y., Muto, K., Kamatani, Y., Ninomiya, T., Matsuda, K., Kubo, M., Nakamura, Y., Tamakoshi, A., 2017, Characteristics and Prognosis of Japanese Female Breast Cancer Patients: The Biobank Japan Project, *Journal of Epidemiology*, 27(2017) S58-S64. <http://dx.doi.org/10.1016/j.je.2016.12.009>.

National Cancer Institute, 2017, *Hormone Therapy for Breast Cancer*,
<http://www.cancer.gov/types/breast> diakses pada tanggal 30 Oktober
2019.

National Cancer Institute, 2019, *Radiation Therapy to Treat Cancer*,
<https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy>
diakses pada tanggal 7 Juli 2020.

Nichols, H.B., DeRoo, L.A., Scharf, D.R., Sandler, D.P., 2015, Risk-Benefit
Profiles of Women Using Tamoxifen for Chemoprevention, *JNCI J Natl
Cancer Inst.*, 1–8 doi:10.1093/jnci/dju354.

Njoku, K., Abiola, J., Russell, J., Crosbie, E.J., 2019, Endometrial Cancer
Prevention in High-Risk Women, *Best Practice & Research Clinical
Obstetrics and Gynaecology*,
<https://doi.org/10.1016/j.bpobgyn.2019.12.005>

Pan, H.J., Chang, H.T., Lee, C.H., 2016, Association Between Tamoxifen
Treatment and The Development of Different Stages of Nonalcoholic
Fatty Liver Disease Among Breast Cancer Patients, *Journal of the
Formosan Medical Association*, 115, 411e417.
<http://dx.doi.org/10.1016/j.jfma.2015.05.006>.

Parikh, P.P., Odom, E.B., Yu, L., Colditz, G.A., Myckatyn, T.M., 2017,
*Complications and Thromboembolic Events Associated with Tamoxifen
Therapy in Patients with Breast Cancer Undergoing Microvascular*

Breast Reconstruction: A Systematic Review and Meta-Analysis, Breast Cancer Res Treatment, 163(1): 1–10. doi:10.1007/s10549-017-4146-3.

Perdrix, A., Ghislain, M.S., Degremont, M., David, M., Khaznadar, Z., Loeb, A., Leheurteur, M., Fiore, F.D., Caltot, F., 2017, Influence of Adjuvant Chemotherapy on Anti-Müllerian Hormone in Women Below 35 Years Treated for Early Breast Cancer, *Reproductive BioMedicine Online*, Volume 35 Pages 468-474, <https://doi.org/10.1016/j.rbmo.2017.06.005>.

Prihandiwati, E., Pratiwi, M.D., Mardiana, Ayuzecharia, N., Ariani, N., Aosyah, N., 2019, Kualitas Hidup Pasien Kanker Payudara di Ruang Edelweis Rsud Ulin Banjarmasin, *Jurnal Ilmiah Ibnu Sina*, 4(1), Maret 2019, 176-185.

Putri, S.B., Achir, Y.S.H., Vetty, P., 2017, Karakteristik dan Strategi Koping dengan Stres Pasien Kanker Payudara dalam Menjalani Kemoterapi, *Jurnal Endurance*, (303 31 1).

Rondonuwu, I.A., Haroen, H., Wantania, F.E., 2016, Profil Kanker Payudara di RSUP Prof. Dr. R. D. Kandou Manado Tahun 2013 – 2014, *Jurnal e-Clinic (eCl)*, Volume 4, Nomor 1, Januari-Juni 2016.

Rukminingsih, F., Andayani, T.M., Rahmawati, F., Widayati, K., 2017, *Evaluasi Terapi Adjuvan dan Kejadian Relaps pada Pasien Premenopausal Early Breast Cancer di RSUP Dr. Sardjito Yogyakarta*, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta, Vol 7 No. 1.

Sideras, K., Ingle, J.N., Ames, M.M., Loprinzi, C.L., Mrazek, D.P., Black, J.L., Weinshilboum, R.M., Hawse, J.R., Spelsberg, T.C., dan Goetz, M.P., 2010, Coprescription of Tamoxifen And Medications That Inhibit CYP2D6, *Journal Of Clinical Oncology*, Volume 28 No. 16, Doi: 10.1200/Jco.2009.23.8931.

Shweta, S., dan Manasi G., 2020, Machine Learning Methods for Computer-Aided Breast Cancer Diagnosis Using Histopathology: A Narrative Review, *Journal of Medical Imaging and Radiation Sciences*, 51(182-193). doi.org/10.1016/j.jmir.2019.11.001

Tang, S., Zhang, Q., Tang, X., Chen, D., Zhang, F., Liu, J., Wei, W., Liu, D., 2019, Long-Term Comparisons of The Efficacy, Safety, and Pregnancy Outcomes of Adjuvant Tamoxifen Plus Ovarian Function Suppression in Premenopausal Han and Zhuang Chinese Patients With Hormone Receptor-Positive Early Breast Cancer, *Journal of International Medical Research*, Vol. 47(2) 641–652. DOI: 10.1177/0300060518807100

Thulin, A., Ronnerman, E., Zhang, C., Lara, S.D., Chamalidou, C., Schoenfeldt, A., Andersson, C., Kovacs, A., Enlund, F., Linderholm, B., 2020, Clinical Outcome of Patients With Brain Metastases From Breast Cancer - A Population Based Study Over 21, *The Breast*, 50 (2020) 113e124. <https://doi.org/10.1016/j.breast.2020.02.007>

UPMC Hilman Cancer Center, 2019, *Medical Oncology and Chemotherapy*, <http://www.hilman.upmc.com> diakses pada tanggal 30 Oktober 2019.

Visvanathan, K., Chlebowski, R.T., Hurley, P., Col, N.F., Ropka, M., Collyar, D.,
Morrow, M., Runowicz, C., Pritchard, K.I., Hagerty, K., Arun, B.,
Garber, J., Vogel, V.G., Wade, J.L., Brown, P., Cuzick, J., Kramer, B.S.,
dan Lippman, S.M., 2009, American Society of Clinical Oncology
Clinical Practice Guideline Update on the Use of Pharmacologic
Interventions Including Tamoxifen, Raloxifene, and Aromatase
Inhibition for Breast Cancer Risk Reduction, *Journal Of Clinical
Oncology*, Vol. 27 No 19 27:3235-3258.

Wahyuni, S.F., Windrasari, W., Khambri, D., 2018, Evaluasi Terapi Adjuvant
Hormonal dan Hubungannya Terhadap Outcome Klinis Pasien Kanker
Payudara Stadium Dini di Kota Padang, *Jurnal Sains dan Farmasi Klinis*,
Vol. 5 No. 3 (Desember 2018) pp. 176–184.

Walker, A.J., West, J., Card, T.R., Crooks, C., Kirwan, C.C., Grainge, M.J., 2016,
*When Are Breast Cancer Patients at Highest Risk of Venous
Thromboembolism? A Cohort Study Using English Health Care Data*,
The American Society of Hematology, Vol. 127 No.7.

Wangsa, I.G.M.S, Nirvana, I.W., Adiputra, P.A.T., Dewi, N.P.A.P.A., 2018,
*Gambaran Stadium dan Jenis Histopatologi Kanker Payudara di Sub
Bagian Bedah Onkologi RSUP Sanglah Denpasar Tahun 2015-2016*,
Intisari Sains Medis 2018, Volume 9, Number 1: 80-84.

William, N., Zuhair, .A.R., Alex, T., Julnar, M., Mahmud, M., 2017, *Relationship Between Non-Alcoholic Fatty Liver Disease and Breast Cancer*, Israel Vol.19.

Yan, M., Wang, J., Xuan, Q., Dong, T., He, J., Zhang, Q., 2016, The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer, *Clinical Breast Cancer*, Vol. 17 No. 3 195-203. <http://dx.doi.org/10.1016/j.clbc.2016.12.004>.

Yulianti, I., Henry S.S., Sutningsih, D., 2016, Faktor-Faktor Risiko Kanker Payudara (Studi Kasus Pada Rumah Sakit Ken Saras Semarang), *Jurnal Kesehatan Masyarakat*, Volume 4, Nomor 4, Oktober 2016 (ISSN: 2356-3346).

Yussof, Siti Wahidah, 2013, *Karakteristik Pasien dan Pola Pengobatan Kanker Payudara di RSUP Dr. Sardjito Yogyakarta Tahun 2012*, Skripsi, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.